A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Inclusion Criteria:

• Native Chinese participants must be of an acceptable age to provide informedconsent.

• Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1).

• Have disease with evidence of KRAS G12C mutation

• Have a histologically or cytologically proven diagnosis of locally advanced,unresectable, and/or metastatic cancer and must be appropriate candidates for studytreatment.

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Have adequate laboratory parameters.

• Must be able to swallow capsules or tablets.

• Estimated life expectancy ≥12 weeks

Exclusion Criteria:

• Have disease suitable for local therapy administered with curative intent.

• Have an active fungal, bacterial, and/or active untreated viral infection,

• Have a serious pre-existing medical condition(s) that would preclude participationin this study.

• Have a serious cardiac condition.

• Have untreated active symptomatic central neural system (CNS) malignancy ormetastasis and/or carcinomatous meningitis.

• Have received prior treatment with any KRAS G12C small molecule inhibitor.

• Females who are pregnant or lactating.

• Have a known allergic reaction against any of the components of the study drug